1. Scrip
  2. >>Business
  3. >>Strategy

Bayer Execs Roth And Eckhardt On Current And Future Pharma Growth

Nubeqa, Kerendia Driving Revenue; New Launches On The Way

 
• By Mandy Jackson

Scrip spoke with Bayer commercial and business development heads Christine Roth and Jurgen Eckhardt about sales growth, product launches and dealmaking priorities in 2025 and beyond.

New launches and added indications will fuel growth in 2025 as Xarelto revenue declines (Shutterstock)
Key Takeaways
  • Bayer’s pharma commercialization head Christine Roth is optimistic about revenue growth in 2025 based on sales gains for newer products in 2024 as well as new indications and launches this year.
  • Nubeqa and Kerendia remain key growth products, with new indications coming for both in 2025, while Beyonttra in the EU and elinzanetant in the US are new launches with good prospects.
  • Early-stage assets are dealmaking priorities, with some notable exceptions. Business development head Juergen Eckhardt noted earlier programs are accessible given current financing dynamics.

Bayer has asked investors for patience as the conglomerate works its way through various challenges across its pharmaceuticals, crop science and consumer health businesses, and in 2024 pharma showed the most progress with sales up nearly 4% during the first nine months of the year

Scrip spoke recently with Bayer’s global head of product strategy and commercialization Christine Roth and head of pharma business development and licensing Jurgen Eckhardt about milestones the company hopes to achieve this

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.